Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders

A meta-analysis

Leticia González-Blanco, Anne Marie D. Greenhalgh, Clemente Garcia-Rizo, Emilio Fernandez-Egea, Brian J Miller, Brian Kirkpatrick

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Objective: The use of dopaminergic antagonist antipsychotics is associated with hyperprolactinemia, but some studies have found increased prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders. We conducted a systematic review and meta-analysis of studies of prolactin in antipsychotic-naïve patient with these disorders (PRISMA No. CRD42015016337). Data sources: PubMed (Medline), PsycInfo, and Web of Science were searched for articles from 1950 to the present in English. Study selection: Seven studies of males (N = 141 for patients, N = 191 for control subjects) and five studies of females (N = 67 and N = 116) met criteria for inclusion: data on blood prolactin concentrations for both control subjects and antipsychotic-naive patients with schizophrenia or a related disorder, with data available separately for males and females. Data extraction: Data was extracted from the papers by one author and independently verified by a second. Results: The mean effect size for males was 1.02 (95% CI, 0.77, 1.26; p < 0.001) and 0.43 for females (95% CI 0.11, 0.76; p < 0.01). Meta-regression analyses for age, smoking, body mass index (BMI), year of publication, and cortisol were not significant. Funnel plots did not suggest the presence of a publication bias. Conclusions: Our meta-analyses found significantly increased prolactin levels in both male and female antipsychotic-naïve patients with schizophrenia and related disorders. The small number of studies and limited matching for potentially confounding variables in some of the studies were limitations of this analysis. Prolonged hyperprolactinemia may lead to sexual dysfunction and osteoporosis, and some antipsychotics cause additional elevation of prolactin concentrations.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalSchizophrenia Research
Volume174
Issue number1-3
DOIs
StatePublished - Jul 1 2016

Fingerprint

Prolactin
Antipsychotic Agents
Meta-Analysis
Schizophrenia
Hyperprolactinemia
Publication Bias
Confounding Factors (Epidemiology)
Dopamine Antagonists
Information Storage and Retrieval
PubMed
Osteoporosis
Hydrocortisone
Publications
Body Mass Index
Smoking
Regression Analysis

Keywords

  • Meta-analysis
  • Prolactin
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders : A meta-analysis. / González-Blanco, Leticia; Greenhalgh, Anne Marie D.; Garcia-Rizo, Clemente; Fernandez-Egea, Emilio; Miller, Brian J; Kirkpatrick, Brian.

In: Schizophrenia Research, Vol. 174, No. 1-3, 01.07.2016, p. 156-160.

Research output: Contribution to journalReview article

González-Blanco, L, Greenhalgh, AMD, Garcia-Rizo, C, Fernandez-Egea, E, Miller, BJ & Kirkpatrick, B 2016, 'Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis', Schizophrenia Research, vol. 174, no. 1-3, pp. 156-160. https://doi.org/10.1016/j.schres.2016.03.018
González-Blanco, Leticia ; Greenhalgh, Anne Marie D. ; Garcia-Rizo, Clemente ; Fernandez-Egea, Emilio ; Miller, Brian J ; Kirkpatrick, Brian. / Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders : A meta-analysis. In: Schizophrenia Research. 2016 ; Vol. 174, No. 1-3. pp. 156-160.
@article{a2ec8678b10c4d2daac4b85c8325d85a,
title = "Prolactin concentrations in antipsychotic-na{\"i}ve patients with schizophrenia and related disorders: A meta-analysis",
abstract = "Objective: The use of dopaminergic antagonist antipsychotics is associated with hyperprolactinemia, but some studies have found increased prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders. We conducted a systematic review and meta-analysis of studies of prolactin in antipsychotic-na{\"i}ve patient with these disorders (PRISMA No. CRD42015016337). Data sources: PubMed (Medline), PsycInfo, and Web of Science were searched for articles from 1950 to the present in English. Study selection: Seven studies of males (N = 141 for patients, N = 191 for control subjects) and five studies of females (N = 67 and N = 116) met criteria for inclusion: data on blood prolactin concentrations for both control subjects and antipsychotic-naive patients with schizophrenia or a related disorder, with data available separately for males and females. Data extraction: Data was extracted from the papers by one author and independently verified by a second. Results: The mean effect size for males was 1.02 (95{\%} CI, 0.77, 1.26; p < 0.001) and 0.43 for females (95{\%} CI 0.11, 0.76; p < 0.01). Meta-regression analyses for age, smoking, body mass index (BMI), year of publication, and cortisol were not significant. Funnel plots did not suggest the presence of a publication bias. Conclusions: Our meta-analyses found significantly increased prolactin levels in both male and female antipsychotic-na{\"i}ve patients with schizophrenia and related disorders. The small number of studies and limited matching for potentially confounding variables in some of the studies were limitations of this analysis. Prolonged hyperprolactinemia may lead to sexual dysfunction and osteoporosis, and some antipsychotics cause additional elevation of prolactin concentrations.",
keywords = "Meta-analysis, Prolactin, Psychosis, Schizophrenia",
author = "Leticia Gonz{\'a}lez-Blanco and Greenhalgh, {Anne Marie D.} and Clemente Garcia-Rizo and Emilio Fernandez-Egea and Miller, {Brian J} and Brian Kirkpatrick",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.schres.2016.03.018",
language = "English (US)",
volume = "174",
pages = "156--160",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders

T2 - A meta-analysis

AU - González-Blanco, Leticia

AU - Greenhalgh, Anne Marie D.

AU - Garcia-Rizo, Clemente

AU - Fernandez-Egea, Emilio

AU - Miller, Brian J

AU - Kirkpatrick, Brian

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Objective: The use of dopaminergic antagonist antipsychotics is associated with hyperprolactinemia, but some studies have found increased prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders. We conducted a systematic review and meta-analysis of studies of prolactin in antipsychotic-naïve patient with these disorders (PRISMA No. CRD42015016337). Data sources: PubMed (Medline), PsycInfo, and Web of Science were searched for articles from 1950 to the present in English. Study selection: Seven studies of males (N = 141 for patients, N = 191 for control subjects) and five studies of females (N = 67 and N = 116) met criteria for inclusion: data on blood prolactin concentrations for both control subjects and antipsychotic-naive patients with schizophrenia or a related disorder, with data available separately for males and females. Data extraction: Data was extracted from the papers by one author and independently verified by a second. Results: The mean effect size for males was 1.02 (95% CI, 0.77, 1.26; p < 0.001) and 0.43 for females (95% CI 0.11, 0.76; p < 0.01). Meta-regression analyses for age, smoking, body mass index (BMI), year of publication, and cortisol were not significant. Funnel plots did not suggest the presence of a publication bias. Conclusions: Our meta-analyses found significantly increased prolactin levels in both male and female antipsychotic-naïve patients with schizophrenia and related disorders. The small number of studies and limited matching for potentially confounding variables in some of the studies were limitations of this analysis. Prolonged hyperprolactinemia may lead to sexual dysfunction and osteoporosis, and some antipsychotics cause additional elevation of prolactin concentrations.

AB - Objective: The use of dopaminergic antagonist antipsychotics is associated with hyperprolactinemia, but some studies have found increased prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders. We conducted a systematic review and meta-analysis of studies of prolactin in antipsychotic-naïve patient with these disorders (PRISMA No. CRD42015016337). Data sources: PubMed (Medline), PsycInfo, and Web of Science were searched for articles from 1950 to the present in English. Study selection: Seven studies of males (N = 141 for patients, N = 191 for control subjects) and five studies of females (N = 67 and N = 116) met criteria for inclusion: data on blood prolactin concentrations for both control subjects and antipsychotic-naive patients with schizophrenia or a related disorder, with data available separately for males and females. Data extraction: Data was extracted from the papers by one author and independently verified by a second. Results: The mean effect size for males was 1.02 (95% CI, 0.77, 1.26; p < 0.001) and 0.43 for females (95% CI 0.11, 0.76; p < 0.01). Meta-regression analyses for age, smoking, body mass index (BMI), year of publication, and cortisol were not significant. Funnel plots did not suggest the presence of a publication bias. Conclusions: Our meta-analyses found significantly increased prolactin levels in both male and female antipsychotic-naïve patients with schizophrenia and related disorders. The small number of studies and limited matching for potentially confounding variables in some of the studies were limitations of this analysis. Prolonged hyperprolactinemia may lead to sexual dysfunction and osteoporosis, and some antipsychotics cause additional elevation of prolactin concentrations.

KW - Meta-analysis

KW - Prolactin

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84962383366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962383366&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2016.03.018

DO - 10.1016/j.schres.2016.03.018

M3 - Review article

VL - 174

SP - 156

EP - 160

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -